Research programme: autologous T cell receptor cancer therapeutics - Kite Pharma/Netherlands Cancer Institute

Drug Profile

Research programme: autologous T cell receptor cancer therapeutics - Kite Pharma/Netherlands Cancer Institute

Alternative Names: TCR cancer immunotherapy - Kite Pharma/ Netherlands Cancer Institute; TCR-based immuno-oncology therapeutics - Kite Pharma/Netherlands Cancer Institute

Latest Information Update: 21 Sep 2015

Price : $50

At a glance

  • Originator Netherlands Cancer Institute
  • Class
  • Mechanism of Action Cell replacements; T-cell receptor gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Solid tumours

Most Recent Events

  • 14 Sep 2015 Kite Pharma and the Netherlands Cancer Institute agree to co-develop and co-promote T-cell receptor therapeutics in the Netherlands for Solid tumours
  • 14 Sep 2015 Early research in Solid tumours in Netherlands (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top